Treat and extend: An international view

Three experts from Canada, Switzerland and Israel provide insights into the nuances of adherence, treatment intervals and emerging therapies.

A closer look at emerging drug-delivery platforms

An update on Port Delivery System with ranibizumab, a large-molecule anti-VEGF candidate and subretinal gene therapy to treat neovascular AMD.

Retinal implant platforms moving from uveitis to AMD

Treatments show potential for various posterior-segment diseases based on their success treating noninfectious uveitis.

Using OCT to evaluate fluid in non-neovascular AMD

How optical coherence tomography, OCT angiography and fluorescein angiography can help direct diagnosis and treatment decisions.

Five emerging treatments show mixed results

Uncertainty about PVL for VMT and aflibercept for NPDR, some clarity on PDT, and early promise for stem cells and a bioresorbable implant.

How imaging is advancing management of dry AMD

Emerging modalities and deep learning are helping to expose an old foe in non-neovascular age-related macular degeneration: reticular pseudodrusen.

Imaging biomarkers and precision medicine

Advances in computational power, and machine learning and diagnostic systems are creating new opportunities for understanding disease mechanisms.

Where genetics, diet and drusen size intersect

A close look at research into how diet may reverse the effect of genetic susceptibility in drusen size progression in age-related macular degeneration.

Will biosimilars find their place in retina?

With patents expiring, an approval pending and legislation aimed at easing regulations, more biosimilars could be coming. But are retina specialists ready?

The complement pathway in geographic atrophy explained

Examining the role of complement factors in advanced disease.

The promise of targeting mitochondria in dry AMD

Mitochondrial therapies have shown the potential to improve visual function in patients with dry age-related macular degeneration.

Understanding role of Ang2 in neovascular AMD

Angiopoietin-2 is an increasingly desirable target in age-related macular degeneration. Here’s why, and an assessment of investigative treatments.

Lessons from CANTREAT: fewer visits, BCVA improvement

Level 1 evidence now supports treat-and-extend vs. monthly intervals for anti-VEGF treatment of neovascular age-related macular degeneration.

Potential of OCT to identify genetic risk in AMD

A look at our work in optical coherence tomography-derived drusen burden in non-advanced age-related macular degeneration.

Has the time come for AMD home monitoring?

An update on the progress of home-based OCT and how it could reduce treatment burden during and beyond the pandemic.

Long-term anti-VEGF effect: Six questions answered

A review of the evidence that suggests the beneficial effects of consistent treatment extend out to 10 years.

Potential of OCT to identify genetic risk in AMD

A look at our work in optical coherence tomography-derived drusen burden in non-advanced age-related macular degeneration.

More frequent dosing for refractory nAMD?

A closer look at biweekly anti-VEGF dosing for chronic disease that doesn’t respond completely to standard monthly dosing.

New revelations for nAMD, CSC treatments and ILM utility

Trial readouts on improving treatment durability, a potential new therapy for central serous chorioretinopathy and adding to the debate of RRD repair.

Gene therapy in AMD: Promises and challenges

Gene therapy could offer long-term stable control and prevent non-compliance, but the long-term effectiveness remains to be seen.

Gene therapy and editing for the retina: A primer

A look at advances in gene replacement therapy, gene delivery and CRISPR technology.

Is drier better in neovascular AMD?

It may depend on the location of the fluid. A quick look at HARBOR post-hoc results.

Pipeline Report: Despite major approvals, the queue gets longer

Treatments for exudative disease were notable for four significant exits from our listing and seven new entries this year.

Pipeline Report: The path to GA treatment: What’s hot, what’s not

A review of past trials that disappointed and current trials that are showing promise as potential treatments.

First results of gene and cell therapies for nAMD, RP, plus ...

Findings on predictors of endophthalmitis, widefield OCT-A vs. FA and microsecond pulsing laser make five worthy takeaways.

Downside of finger flicks, upside of abicipar changes

These findings and three other presentations on SRF/IRF, stable CST and oral therapy give new insights into nAMD.

20 milestones ahead in AMD, DME meds

A look at chemical and biologic agents queued this year or next for key steps toward commercialization.

Targeting Unmet Needs in nAMD Treatment

A look at longer-acting anti-VEGF agents, sustained-release delivery, gene therapy and novel molecules in development.

The Choroid in AMD: A Critical Point of Failure?

Advancements in imaging and new computational models are improving our understanding of choroidal failure.

Video Vault

Minimally invasive management of lenticular deposits

Akshay Thomas, MD, MS, of Tennessee Retina demonstrates his surgical technique for removing posterior intraocular lens deposits.